Short-Term Outcomes of Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement in Kidney Transplant Recipients (From the US Nationwide Representative Study).
Kidney transplant recipients (KTRs) are considered high-risk patients for surgical interventions. Transcatheter aortic valve implantation (TAVI) has been introduced as an alternative to surgical aortic valve replacement (SAVR) in patients with aortic stenosis (AS) at high operative risk. However, the outcomes of TAVI compared to SAVR KTRs have not been well-studied in nationally representative data. Patients with prior history of functioning kidney transplant who were hospitalized for TAVI and SAVR between January 2012 and December 2017 were identified retrospectively in the Nationwide Readmissions Database. Our study included 762 TAVI and 1,278 SAVR KTRs. Compared to SAVR, TAVI patients generally had higher rates of comorbidities with lower risk of in-hospital mortality (3.1% vs. 6.3, P=0.002), blood transfusion (11.5% vs. 38.6%, P<0.001), acute myocardial infarction (3.9% vs. 6.5%, P=0.16), acute kidney injury (24.5% vs. 42.1%, P<0.001), sepsis (3.9% vs. 9.5%, P<0.001) and discharge with disability (42.6% vs. 68.4%, P<0.001). However, the rate of permanent pacemaker implantation was significantly higher in TAVI group (11.4% vs. 3.9%, P<0.001). Of note, in-hospital stroke and 30-day readmission were comparable between both groups. These findings were confirmed after adjusting for other comorbidities. TAVI is growing as a valid and safe alternative for KTRs with severe AS.